(Q37854742)

24 August 2017

1 reference

title

Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy (English)

1 reference

systemic lupus erythematosus

24 August 2017

0 references

1 reference

1 reference

1 reference

4

Wilbert S Aronow

1 reference

24 August 2017

Crispin Abarientos

1

1 reference

24 August 2017

Kirk Sperber

2

1 reference

24 August 2017

Deborah L Shapiro

3

1 reference

24 August 2017

Chun Peng Chao

5

1 reference

24 August 2017

Julia Y Ash

6

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 March 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

5

1 reference

24 August 2017

705-714

1 reference

Antimalarial drugs in the treatment of rheumatological diseases

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Acidification of the endocytic and exocytic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Pharmacogenetics of disease-modifying anti-rheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Inhibition of mitogen-activated protein kinase signaling by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

IL-17 and the Th17 lineage in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

New insights into the antiviral effects of chloroquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

21 January 2018

Methotrexate nodulosis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Successful desensitization for hydroxychloroquine anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Influence of hydroxychloroquine on the bioavailability of oral metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Multifocal electroretinographic evaluation of long-term hydroxychloroquine users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Antimalarial drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Antirheumatic drugs in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Ocular adverse effects associated with systemic medications : recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Evidence of transplacental passage of hydroxychloroquine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Anti-inflammatory and immunosuppressive drugs and reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Antimalarial drugs in systemic lupus erythematosus: use in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine in lupus pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Management of RA medications in pregnant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Antimalarial agents in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Pregnancy outcome following first trimester exposure to chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.566555

10.1517/14740338.2011.566555

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference